Two of the fastest-growing prescriptions among women in their 40s and 50s are GLP-1 medications and menopausal hormone therapy (HRT). A lot of women are on both, or considering both — and the most common question we hear in intake notes is some version of: "I'm on HRT. Can I take this too?"
The short answer: there is no known direct interaction between the hormones used in HRT and semaglutide or tirzepatide. But there is one mechanism worth understanding — GLP-1 medications slow stomach emptying, which can affect how oral medications are absorbed — and it's the reason the route of your hormones (pill vs. patch vs. gel) is worth a specific conversation with your clinician.
The one-paragraph version
No direct hormone-to-GLP-1 interaction has been established. Transdermal estrogen (patches, gels, sprays) and vaginal preparations bypass the gut entirely, so slowed stomach emptying is not a factor. Oral hormones are absorbed through the gut, and the tirzepatide prescribing information specifically advises women using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. Tell your clinician exactly which hormones you take and by what route — that one detail drives the guidance.
Why this combination is suddenly so common
The menopause transition changes body composition in a way the scale only partially captures. In the SWAN study — which followed a multi-ethnic cohort of women across the menopause transition — fat mass increased and lean mass declined during the transition years, with fat preferentially accumulating centrally, even in women whose total weight changed little.
At the same time, hormone therapy has been rehabilitated for the right candidates. The Menopause Society's 2022 position statement supports hormone therapy as first-line treatment for moderate-to-severe vasomotor symptoms in appropriate candidates, generally women under 60 or within 10 years of their final period.
So a growing number of women are treating menopause symptoms with HRT and, separately, working on midlife weight with a clinician — sometimes with a GLP-1. The two conversations often happen with two different prescribers, which is exactly how route-of-administration details fall through the cracks.
What GLP-1s do to oral medication absorption
Semaglutide and tirzepatide slow gastric emptying — food and pills sit in the stomach longer. For most oral medications this doesn't meaningfully change drug exposure, but it can for some, and the effect is largest right after starting and after each dose escalation, before the stomach partially adapts.
Here is the practical breakdown by hormone route:
| Your hormone route | Affected by slowed stomach emptying? | What to discuss |
|---|---|---|
| Transdermal estradiol (patch, gel, spray) | No — absorbed through skin | Generally no change needed; confirm with your prescriber |
| Vaginal estrogen (cream, ring, tablet) | No — local absorption | Generally no change needed |
| Oral estradiol or conjugated estrogens | Potentially — absorbed via the gut | Ask your prescriber whether route or timing should change |
| Oral progesterone (micronized) | Potentially — absorbed via the gut | Same conversation; often taken at night, which helps consistency |
| Oral contraceptive pills (still common in perimenopause) | Yes — specific label guidance exists for tirzepatide | See below |
The clearest guidance in this area is for birth control pills with tirzepatide: the Zepbound® and Mounjaro® prescribing information advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation. The Wegovy® prescribing information, by contrast, reports no clinically significant effect of semaglutide on oral contraceptive exposure.
That matters in perimenopause for a reason many women don't love hearing: until you've gone 12 months without a period, pregnancy is still possible — and GLP-1 medications are not used during pregnancy.
Does HRT help with weight itself?
Hormone therapy is not a weight-loss treatment, and The Menopause Society does not recommend it for that purpose. What the evidence does suggest is subtler: in randomized trials, women on hormone therapy did not gain more weight than women on placebo (a persistent myth), and some analyses suggest estrogen therapy may lessen the central redistribution of fat that the transition drives. Treating disruptive symptoms — especially night sweats that wreck sleep — can also indirectly support weight efforts, since short sleep reliably pushes appetite and food choices in the wrong direction.
If your goal is meaningful weight loss, HRT is not the tool. That's a separate clinical conversation — about lifestyle, strength training, protein, and, for some women, GLP-1 therapy prescribed by a licensed clinician.
How a clinician thinks through the combination
There's no rule that you must choose one or the other. What a careful clinician does is sequence and coordinate:
- Full medication list, with routes. "Estradiol" isn't enough — patch vs. pill changes the guidance. List every hormone, dose, and route in your intake.
- One change at a time when possible. Starting HRT and a GLP-1 the same week makes it hard to tell which medication caused which effect. Many clinicians stagger starts by a few weeks.
- Contraception check in perimenopause. If pregnancy is still possible, your clinician will address contraception explicitly — especially with tirzepatide, per its label guidance.
- Symptom overlap awareness. Early GLP-1 side effects (nausea, fatigue) can blur into perimenopausal symptoms. Knowing your baseline before starting helps your care team attribute changes correctly.
Keep both prescribers in the loop
If your hormones come from one clinician and your weight-management care from another, tell each about the other's prescriptions — including over-the-counter progesterone creams and compounded hormone preparations. Absorption questions can't be answered about medications your clinician doesn't know exist.
Where Pallas fits
Pallas doesn't prescribe hormone therapy. What we do is ask about it — your intake collects every medication you take, including hormones and their routes, and a US-licensed clinician reviews that history before deciding whether a GLP-1 is appropriate for you. If you use HRT, that's not a disqualifier; it's context your clinician factors into the recommendation and your titration plan.
Frequently asked questions
No direct interaction between GLP-1 medications and the hormones themselves has been established. The relevant mechanism is indirect: GLP-1s slow stomach emptying, which can affect how orally taken medications are absorbed. Transdermal (patch, gel, spray) and vaginal hormone preparations bypass the gut entirely, so that mechanism doesn't apply to them.
Often no — especially if your estrogen is transdermal or vaginal, which isn't affected by slowed stomach emptying. If you take oral estradiol or oral progesterone, raise it with your prescriber: route or timing adjustments are sometimes discussed, particularly around dose escalations. Never change your hormone regimen on your own.
Tirzepatide's prescribing information (Zepbound® and Mounjaro®) specifically advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation. The Wegovy® (semaglutide) prescribing information reports no clinically significant effect on oral contraceptive exposure. Until you've gone 12 months without a period, pregnancy is still possible — and GLP-1s are not used during pregnancy.
Randomized trial evidence says no — women on hormone therapy did not gain more weight than women on placebo. Some analyses suggest estrogen therapy may lessen the shift of fat to the abdomen that the menopause transition drives. But hormone therapy is not a weight-loss treatment and isn't recommended for that purpose.
Usually not simultaneously. Many clinicians prefer to stagger the starts by a few weeks so that side effects can be attributed to the right medication — early GLP-1 effects like nausea and fatigue can blur into perimenopausal symptoms. The sequencing is a clinical decision made with your prescriber(s), and each should know about the other's prescriptions.
References
- Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865.
- The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
- Zepbound® (tirzepatide) prescribing information. Eli Lilly and Company.
- Wegovy® (semaglutide) prescribing information. Novo Nordisk.
Bottom line: HRT and GLP-1 therapy are frequently prescribed to the same women, and no direct interaction between them has been established. The detail that matters is the route of your hormones: transdermal and vaginal preparations bypass the gut; oral hormones deserve a specific conversation — and oral contraceptives with tirzepatide come with explicit label guidance. Put every hormone, dose, and route in your intake and let a licensed clinician coordinate the rest.
On HRT and wondering about GLP-1 therapy?
List your hormones and their routes in a 5-minute intake, and a US-licensed clinician will review whether GLP-1 treatment is appropriate alongside them — and flag anything that needs coordination.
Start your intake →